I expect MM to brief trial results to Gilead, GSK ......

I expect MM to brief trial results to Gilead, GSK ...

GlaxoSmithKline HIV study shows 'positive' results
By Carlo Martuscelli
Published: Oct 29, 2018 7:25 a.m. ET


0
Time (EDT)Pfizer Inc.10:0011:0012:001:002:003:00
$42.00$42.25$42.50$42.75$43.00$43.25$43.50
ViiV Healthcare, majority-owned by GlaxoSmithKline PLC (GSK.LN), said a phase 2 trial of a two-drug regimen to treat HIV showed positive results.

The Latte-2 trial is a phase 2 study examining an injectable cabotegravir and rilpivirine administered either every eight or four weeks over the course of 160 weeks. The company said the regimen showed a high-rate of virus response, durability and was tolerated well by patients overall.

ViiV said that at 160 weeks, 90% of patients taking the two-drug combination every eight weeks had suppressed levels of HIV, with the level decreasing to 83% for patients receiving it every four weeks. The treatment failed for two patients whose viral loads exceeded an acceptable threshold.

The HIV-focused drug-development company said a majority of participants developed an inflammation at the injection site. Other common side effects included colds, diarrhea and headaches. ViiV said that 3% and 10% of patients had adverse reactions leading to withdrawal and discontinuation of treatment for the eight-week and four-week regimens respectively.

ViiV Healthcare is majority-owned by Glaxo, with Pfizer Inc. PFE, -1.87% and Shionogi Limited also holding stakes.